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Abstract
Objective
VulvoVaginitis is the most common gynecological problem affecting millions of women
world wide. At some point in their life time, nearly 75% of all women experience an attack of
Candida Vulvovaginitis. Little is known about the prevalence of different causes of
Vulvovaginitis and risk factors for this entity in Saudi Arabia. This survey was conducted to
study the etiologic agents associated with mycotic Vulvovaginitis and review some
predisposing factors correlated with this type of infection in Al -Madina AI- Munawarah,
Saudi Arabia.
Methods
High vaginal swabs (HVS) specimens were collected from 1000 patients attending
gynecological out patients clinics of two general hospitals in AI-Madinah AI-Munawarah .
Specimens were cultured on specific medium for yeasts and identification of the positive
isolates was carried out using "API" kit. Antifungal sensitivity pattern of the isolates was
tested out using "Candifast" kit. Proteolytic enzyme activity of the isolates was also detected.
Results
Three hundred and forty nine positive cases of yeast infection out of 1000 diagnosed cases
representing 34.9% were recorded in this study. These positive cases were classified on the
basis of the risk factor as; diabetic (28.9%); pregnant, (32.1%); pregnant and diabetic (7.5%);
Menopause (5.5%); oral contraceptive users (10.6%); post hysterectomy (1.4%) and no
observed factor in 14% of the cases. Twenty one different species belonging to 7 genera were
recovered in this study. The genus Candida was the most common (93.4%) and included 14
different species. Candida albicans was the highest in prevalence (51.3%). The non-Candida
species were Saccharomyces cervisiae (2.9%); Rhodotorula rubra (1.1%); R. minuta (0.9%)
Debaryomyces hansenii (0.6%); Trichosporon mucoides (0.6%); Cryptococcus neoformans (0.3%) and
Pichia ohmeri (0.3%). Most of the Candida species were sensitive towards nystatin,
amphoterian B and fluconazole and resistant to other azole drugs. Saccharomyces cervisiae and
Debaryomyces hansenii were sensitive to almost all the tested antifungal drugs.The rest of the
species were variable in their pattern. Proteolytic activity of C. albicans reached its maximum
value after 72 hours. Neutral proteases was the highest at pH 6.5 followed by alkaline
proteases at pH 8.2 and the least amount was acid protease at pH 3.5.
Conclusion
The results of this survey which is the first study done in this region threw some light on the
prevalence, etiology, sensitivity profile of the etiologic agents and the risk factors of
Vulvovaginitis in AI-Madina AI-Munawarah Saudi Arabia. Awareness towards the increase
incidence of Vulvovaginits needs more attention to be paid for fungal infection and
antifungal sensitivity.
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Introduction
VUlvo~agi~tis i~ a gene~al term used todescribe infection or Inflammation of
the Vulva and vagina. Inflammation of
vagina due to infectious agents is very
common, both as an overgrowth of normal
or common colonizers, or as a frank
infection. The most common causes of
Vulvovaginitis are yeast, bacteria, protozoa,
viruses and parasites.'. Egan- had reported
that Vulvovaginitis is the most frequently
gynecological diagnosis encountered by
physicians who provide primary care to
women.
There are number of vaginal candidiasis risk
factors have been identified. The increased
susceptibility of women to develop vaginal
candidiasis is known to be correlated with
the high levels of reproductive hormones
and increase in the glycogen content in the
vaginal environment. The incidence in the
overall population is found to be increased
significantly during pregnancy; in those
using high dose estrogen contraceptive pills,
after an antibacterial treatment regime, and
was also more frequently reported in
diabetic women 3.
Vulvovaginitis caused by Candida species
represents 20-30% of the overall infection. It
is a common cause of morbidity, in women.
Some women have infrequent occasional
episodes of varying severity that respond to
antifungal treatment, while others suffer
from recurrent, often chronic candidiasis 4.
Candida albicans was the most common type
of yeast infection (91.8%). Odds" had found
that C. glabrata to be common yeast other
than C. albicans to be isolated. Certain yeast
species are commonly associated with
antifungal resistance. Resistance to
amphotericin B has been demonstrated in
Candida lusitaniae 6, other Candida spp. Such
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as, C.guilliermondii C. inconspicua, C. kefyr, C.
krusei, C. rugosa', and Trichosporon Sp.8.
Additionally, azole (e.g fluconazole)
resistance has been demonstrated
repeatedly in C.glabrata and C.krusei 9.
The invasion of host tissues by microbial
cells possesses constitutive or inducible
hydrolytic enzymes which destroy or
degrade constituents of cell membranes
leading to membrane dysfunction and or
physical disruption. Since host cell
membranes are made up from lipids and
proteins, it is obvious that these biochemical
processes include the largest part of enzyme
attack'",
The production of hydrolytic enzymes,
especially secreted aspartic proteinases, as
key virulence to determinants has been
comprehensively studied 11. Proteinase
production by C. albicans is associated with
pathogenicityt-.P Proteinase enzyme is
located as a mannoprotein, functions as a
ligand for attachment to host cells and was
identified as virulence determinantl-.
Materials and Methods
Selection ofSubiects
One thousand patients attending
gynecological outpatients clinics of two
general hospitals (Ohod and the Maternity
hospitals in Al-Madinah AI-
Munawarah),complaining of vaginal
discharge and itching, over a period of 8
months ( October ,2007 to May ,2008 ) were
tested for the presence of Vulvovaginal
fungal infection.
Collection of the clinical samples
This study protocol was approved by the
Deanship of Scientific Research of Taibah
University, Al-Madinah AI-Munawarah,
Saudi Arabia.
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High vaginal swabs (HVS) specimens were
taken from each patients, Each HVS was
cultured on a Sabouraud dextrose agar
(SDA) plate (supplemented with 500
mg/liter of chloramphenicol .The plates
were incubated at 37 C for 5 to 7 days before
discarding as negative. Only patients who
yielded heavy growth of yeasts in culture
were selected for the study. Other Bacterial,
Parasitic infections were not tested in this
study.
The following tests were carried out for each
culture",
• Purification of the culture.
• Yeast morphology on corn & rice-meal
tween 80 agar media
• Germ tube test
API 20 C AUX for identification of the yeast
isolate
Identification of the isolates was carried out
using API 20 CUX kit (Bio Merieux, SA
Marcy- L' Etoile, France)16.
The pathogenic potentialities of the isolates
were tested for
• Production of proteolytic enzymes.
• Production of lipolytic enzymes
• And Blood Haemolysis: 17
Sensitivity of the isolated strains to some
antifungal agents using "Candifast ES Twin
Kit".
Antifungal sensitivity testing of pathogenic
Candida species were carried out using
"CANDIFAST ES Twin kit" (ELITECH,
France SAS)18. It provides a sensitivity
profile against 7 antifungal agents
(amphotericin B, nystatin, flucytosine,
econazole, ketoconazole, miconazole and
fluconazole).
Quantitative determination of proteolytic
enzymes activity19,2o.
Enzyme assay
0.1 M sodium citrate buffer containing 2 gm
BSA/litre and the pH adjusted at 3.5, 6.5
and 8.5.
• Culture supernatant, assay medium were
kept on ice.
• Reaction starts by adding 0.1 ml
supernatant + 0.9 ml assay medium.
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• Rapidly shaking at 37°C for 10 min.
• Add equal volume of 5% trichloroacetic
acid.
• After and additional 10 min, the reaction
mixture was centrifuged.
• The supernatant was decanted, and the
absorbance at 280 nm was read against
blank containing distilled water.
Enzyme units are expressed as the amount
of tyrosine in micromoles released per
minute per milliliter of culture supernatant
(108cells of Candida species).
At the same time of enzyme assay, the
growth rate was determined (absorbance at
660nm).
Results
Out of 1000 female patients (ranged from 16
to 65 years) attending the out patients
gynecological clinics with Vulvovaginal
itching and discharge, Candida species and
other non- Candida were isolated from 349
out of the 1000 tested case. Positive cases
represented 34.9% (Table 1). Positive cases
were classified according to the suspected
predisposing factor for fungal infection: 101
diabetic (28.9%), 112 pregnant (32.1%), 26
pregnant and diabetic (7.5%), 19 Menopause
(5.5%), 37 oral contraceptive (10.6%), 5 post-
hysterectomy (1.4%) and 49 with no
observed factors (14%) as shown in Table 2.
Patients were classified into 5 groups
according to their age. The maximum
positive cases were recorded in the second
group (age range 26-35) followed by the first
group (age range 15-25) shown in Table 3.
Data of Table 6 revealed that 21 yeast
species were identified belonging to 7
genera; Candida, Cryptococcus, Debaryomyces,
Pichia, Rhodotorula, Saccharomyces and
trichospron.
The prevalence of non-Candida species was
6.6% (23/349) (Table 6). The non-Candida
isolates included; Saccharomyces cervisiae 10
(2.9%); Rhodotorula rubra 4 (1.1%)
Rhodotonula minuta 3 (0.9%), 2 case of each:
Debaryomyces hansenii, and Trichosporon
mucoides each representing 0.6% and one
case of each of Cryptococcus neoformans and
pichia ohmeri (representing 0.3% in Table 6).
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In this study, the genus Candida recorded
the highest prevalence 326 caes representing
93.4% of the total positive. Candida albicans
was the most prevalent species recovered in
this study. It was isolated from 179 case
constituting 51.3% of the positive cases.
Candida glabrata came next in rank; it was
isolated from 78 case constituting 22.3% of
the positive cases. Candida lusitaniae, C.
tropicalis C. pseudotrepicalis and C. krusei were
of low occurrence representing 5.4%, 4.3%,
3.4% and 2.6 respectively. The rest of the
isolated Candida spp. were of rare
occurrence (Table 6).
Candida albicans recorded the highest
isolation rate in all studied groups. It was
recovered as follows: 54 cases out of 101 in
Table 1: Prevalence rate of the test sample
diabetic group, 62 out of 112 in the pregnant
group, 14 out of 26 of the diabetic - pregnant
group; 9 out 19 in Menopause group, 21 out
of 37 in oral contraceptive group, 2 out of 5
in post hysterectomy group and 17 out of 49
in the unobserved factor group (Table 5).
The tested species proves their ability to
hydrolyze casein and fat which indicted
their potentiality and their implication in the
pathogenesis process. Also almost all
(except Saccharomyces and Debaryomyces spp.)
isolates were positive in the blood
haemolysis test which proves their invasive
and disseminated form.
Samples
Patients
Total rested samples
1000
Positive cases
349
Percentage 0/0
34.9
Table 2: Distribution of yeast positive cases according to suspected predisposing factors
Predisposing Factor
Diabetic
Pregnant
Pregnant and Diabetic
Menopause
Oral contraceptive
Post-hysterectomy
No observed factor
No. of Cases
101
112
26
19
37
5
63
Percentage
0/0
28.9
32.1
7.5
5.5
10.6
1.4
14
126
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Table 3: Distribution of yeast positive cases according to patient's age
Groups of patients
15-25
26-35
36-45
46-55
56-65
No. of cases
118
135
64
28
4
Percentage 0/0
33.8
38.7
18.3
8.1
1.4
Total
Table 4: Frequency and percentage of isolated genera and species of yeasts from test sample
14 326
179 51.3
78 22.3
19 5.4
15 4.3
12 3.4
9 2.6
4 1.1
3 0.9
2 0.6
1 0.3
1 0.3
1 0.3
1 0.3
1 0.3
1
10 2.8
2
4 1.1
3 0.9
1
1 0.6
1 0.6
2
1
1 0.3
1
1 0.3
General and species of
yeast
Candida
(1) C. albicans
(2) C. glabrata
(3) C. lusitaniae
(4) C. tropicalis
(5) C. pseudotropicalis
(6) C. Krusei
(7) C. famata
(8) C. guilliermondii
(9) C. parapsilosis
(10) C. ciferii
(11) C. dubliniensis
(12) C. pelliculosa
(13) C. rugosa
(14) C. zylanoides
Saccaromyces
(15) S. cervisiae
Rhodutorula
(16) R. ruburu
(17) R. minuta
Debaryomyces
(18) D. hansenii
Trichosporon
(19) T. mucoides
Cryptococcus
(20) C. neoformans
Pichia
(21) P. ohmeri
No. of species No. of cases
Total
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Table 5 : Distribution of the isolated yeast species among the different groups of patients
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Table 6: Percentage of Sensitivity and Resistance of the isolated pathogenic yeast towards the common antifungals
Organism
C. albicans
C. glabrata
C. tropicalis
C. lusitaniae
C. pseudotropicalis
C. Krusei
Ci famaia
C. guilliermondii
C. Parapsilosis
C.Ciferii
C. dubiliensis
C. pelliculosa
C. rugosa
C. Zylanoides
Saccharomyces
cervisiae
Rhodotorularubra
R. minuta
Debaryomyces
hansenii
Trichosporon
mucoides
Pichia ohmari
Cryptococcus
neo ormaus
11 ••_ ••••••••
179 67.8 32.2 82 18 78 22 78.5 21.5 70.6 29.4 49.7 50.3 53.7 46.3
78 64.1 35.4 84.6 15.4 62.8 37.2 65.4 34.6 52.6 47.4 30.8 69.2 37.2 62.8
19 84.2 15.8 89.5 10.5 100 a 89.5 10.5 73.7 26.3 47.4 52.6 31.6 68.4
15 66.7 33.3 66.7 33.3 80 20 66.7 33.3 80 20 53.3 46.7 46.7 53.3
12 75 25 91.7 8.3 50 50 50 50 58.3 41.7 41.7 58.3 83.3 16.7
12 33.3 66.7 83.3 16.7 25 75 33.3 66.7 33.3 66.7 16.7 83.3 58.3 41.7
4 25 75 50 50 50 50 25 75 25 75 25 75 25 75
3 a 100 66.7 33.3 66.7 33.3 33.3 66.7 33.3 66.7 33.3 66.7 33.3 66.7
2 a 100 100 a a 100 a 100 a 100 a 100 100 a
1 100 a 100 a 100 a 10 a 100 a 100 a 100 a
1 100 a 100 a 100 a a 100 a 100 a 100 a 100
1 100 a 100 a 100 a 100 a 100 a 100 a a 100
1 100 a 100 a 100 a 100 a 100 a 100 a 100 a
100 a 100 a 100 a a 100 a 100 a 100 a 100
10 80 20 90 10 90 10 80 20 80 20 70 30 70 30
4 75 25 25 75 50 50 50 50 50 50 75 25 75 25
3 66.7 33.3 66.7 33.3 66.7 33.3 66.7 33.3 66.7 33.3 66.7 33.3 66.7 33.3
2 100 a 100 a 100 a 100 a 100 a 50 50 100 a
2 50 50 50 50 50 50 25 75 50 50 a 100 75 25
1 100 a 100 a 100 a a 100 a 100 a 100 100 a
1 100 a 100 a 100 a 100 a 100 a a 100 100 a
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Anti fungal sensitivity testing of the
isolated species
Sensitivity testing of the isolated species was
carried out using candi fast kit. It provides a
sensitivity profile against 7 anti fungal
agents (Ampoteriin B, Nystatin, 5-
flurocytosine, Econazole, Ketonazole,
Miconazole and Fluconazole).
The test showed that most Candida isolates
were sensitive to Nystatin. Most of the
isolates of Candida albicans (80%), the most
common species in this investigation was
also sensitive to Nystatin, Amphotericin B
and some Azole compounds especially
Fluconzole.
Almost all the isolates of Saccharomyces
cervisiae and the two isolates of Debaryomyces
hansenii were sensitive to all antifungal
drugs (Table 6).
Data in Table 6 showed the variable
response of the other isolated species
towards the tested antifungal drugs used in
this study.
Production of extracellular proteinases by
Candida albicans
In this study the determination of the acid,
neutral and alkaline proteases activities was
carried out at the following pH values (3.5,
6.5 and 8.5). The growth rate and enzyme
activity were determined every 12 hours for
a total incubation time of 96 hours. Table 7
and Figure 1 showed that the proteolytic
activity reach its maximum values after 72
hours. This result was relevant to maximum
growth rate of the tested strain, C. albicans.
The proteolytic activity of C. albicans that
measured at pH 3.5 reached its maximum
value of 685 umol / ml. Also the proteolytic
activity of C. albicans reach to the value of
643 umol / ml at pH 8.2. From the above
results, it was found that the neutral
proteases (pH 6.5) were released in
appreciable amounts in C. ablicans followed
by alkaline proteases (pH 8.2) while the least
amount recorded was of acid proteases (pH
3.5) Table 8.
Protease enzyme productivity [umol] tyrosinefml
Inc. Period
pH value
Table 7: Protease enzyme productivity at different incubation periods by C. albicans at
pH value 3.5, 6.5 and 8.2Ea:...._ ........_
pH 3.5
pH 6.5
pH 8.2
335
455
575
395
543
758
383
528
478
427
595
557
461
608
580
493
685
643
345
486
413
409
592
535
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Figure1: Protease enzyme productivity at different incubation periods by C. albicans at pH values 3.5, 6.5
and 8.2
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Table 8: Protease standard values using different tyrosine concentrations at pH values
3.5, 6.5 and 8.2
pH value
Tyrosine conc. H3.5
O.D.
H6.5 H8.2
diabetic (7.5%), menopause (3.4%), post-
hysterectomy 1.4% and (14.1%) with no
observed factors.
It is well documented that pregnancy and
diabetes mellitus increases the rate of
vaginal colonization and infection with
Candida24,22,25 . Potential risk factors for
Vulvovaginal candidiasis have been
identified, including women of child
bearing age, post menopausal women who
have underlying risk factors such as
hormone replacement therapy or
immunosuppression caused by medications
or diseases , using high estrogen containing
combined oral contraceptive pills, vaginal
douching, some sexual behaviors,
contraception devices, (diaphragm,
intrauterine device etc.) and antibiotics
26,27,28,25 .Concerning the etiology in the
present study, the genus Candida
(represented with 14 species) was the most
common etiologic agent documented by
culture, microscopy and the results of the
API Kit. This genus constituted 93.4% of the
total positive cases, while the prevalence of
the non-Candida genera was 6.6% of the
total positive cases. This result is similar to
that of Saporiti et a[29. Candida albicans was
by far the most common pathogen detected
in this study (51.3% of the positive cases).
Vasquez et al.3D reported that, the major
opportunistic pathogen has been Candida
albicans. The proportion of genital C. albicans
in symptomatic women ranges from
approximately 90% in Australian samples31
to approximately 65% in Belgium", Turkey'"
and Saudi Arabia's, The non-albicans
Candida species isolated during this study
represented 42.1% including C. glabrata
(22.3%), C. tropiclis (5.4%), C. lusitaniae
0.032
0.056
0.070
0.087
0.118
0.178
Discussion
Over the last several decades, medical
advances have become available that make
human life more safe. Factors such as
transplant surgery and concomitant
immunosuppressive therapies, anti-cancer
therapies, medical devices that traverse the
protective skin barrier (e.g. central venous
lines, catheters, etc.), broad spectrum
antibacterial therapies, corticosteroid
therapies, certain disease states (e.g.
malignancy, human immunodeficiency
virus infection, etc.), and others have
contributed to increased numbers of
immunocompromised individuals. These
immune-deficient individuals are at higher
risk for yeast infections and the spectrum of
offending species is ever increasing. Species
that were considered to be saprophytic are
becoming opportunists causing human
diseases?'.
In the present study, 349 (34.9%) positive
cases were recovered out of 1000 tested
patients.
This result is in agreement with that of
Margriti-' , who reported that mycotic
Vulvo vaginitis is the most common clinical
manifestation of fungal infections causing
human mycoses; the incidence occurs in
10% of women, while, during pregnancy the
incidence achieves 30% of cases. Candida
species was the most common pathogen in
35.5% of symptomatic women and 15% of
asymptomatic controls-" . Data of this study
revealed that yeast vaginal infection among
the classified groups of patients was;
pregnant (32.1%) diabetic (28.9%), oral
contraceptive users (10.6%), pregnant and
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0.033
0.065
0.079
0.086
0.108
0.166
0.026
0.036
0.062
0.087
0.098
0.178
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(4.3%), C. pseudotropiclis (3.4%), C. Krusei
(2.6%), C. famata (1.1%), C. guilliermondii
(0.9%), C. parapsilosis (0.6%) and the
following species C. ciferii, C. dubliniensis, C.
pelliculosa, C. rugosa and C. zylanoides were of
rare occurrence and each represented 0.3%
of the total positive cases. This study
confirmed that Candida glabrata currently
ranks second as causative agent of vaginal
candidal infection and are common in
immunocompromised persons or those with
diabetes mellitus as reported by Geiger et
al28 and Paul et al14 Two specialized clinics
had reported rates of 10% to 20% of non-
albicans Vulvovaginal candidiasis, and
Candida glabrata had consistently been the
dominant species 27, 35. It is worth
mentioning that there is a variation in the
yield of the species of Candida, where 14
species were recovered belonging to this
genus, some of them may be reported as
causal agent of Vulvovaginitis rarely or for
the first time. Saccharomyces cervisive (2.9%);
Rhodotorula rubra and minuta (2%); each of
Debaryomyces hansenii and Trichosporon
mucoides represented (0.6%) and 0.3% for
each of Cryptococcus neoformans and Pichia
ohmeri. This list was also reported as causal
agents of vaginitis by many authors2,36,37
while other species were recorded as causal
agents of other clinical cases 38,39 • It was
surprising to report one case caused by
Cryptococcus neoformans. Cryptococcal
infection is opportunistic and occurs most
commonly in immunocompromised
patients. Cryptococcal infection usually
presents as meningoencephalitis or
pulmonary infection. Skin, bone and genital
infections are very rare 41. Cryptococcal
infection of the vagina was reported before
by Chen et a1.42 and Ranganathan et a1.43•
The case recorded in the present study is
one of the rare cases to report cryptococcal
vaginitis. Drug resistance is a major problem
in treating yeast infectionsw, At present,
yeast infections are usually treated as a
general fungal infection and agents such as
the polyene, amphotericin B or the newer
azole drugs, which are intended to control a
broad array of fungi, are usedv, The Candida
species collected during this study with high
frequency rate (C.albicans, 179 strain and
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C.glabrata, 78 strain),gave meaningful data
with the sensitivity test. The overall of
C.allbicans isolates showed resistance to "AB
(32.2%); NY (18%); FCT (22%); ECZ (21.5%);
KTZ (29.4%); MCZ (50.3%) and FCZ (46.3%).
While C. glabrata showed the following
resistance pattern "AB (35.4%); NY (15.4%);
FCT (37.2%); ECZ (34.6%); KTZ (47.4%);
MCZ (69.2%) and FCZ (62.8%). Other
collected species with low or rare frequency
gave meaningless data with the antifungal
sensitivity test. Generally the incidence of
amphotericin B- resistant candida species in
our study was 35.5%; Nystatin 17.5%
Fluctosine 27.9%; Econazole, 29.4%;
ketokonazalo 36.5%; Miconazole, 57.4% and
Fluconazole, 51.2%. This incidence of
antifungal resistant candida species in our
results is higher than that reported by other
studies 45,46,47,48. Sanglard and Odds 50
concluded that Candida albicans and related
species pathogenic to man become more
resistant to antifungal agents, in particular
triazole compounds, by expression of effux
pumps that reduce drug accumulation,
alteration of membrane sterol composition
resistance towards most of the tested
antifungal drugs. In the case of
Vulvovaginal candidiasis, an analysis of
clinical isolates indicates that resistance is
due to not only to resistant strains of C.
albicans but also to an increasing number of
non-albicans Candida strains. Various Candida
species appear to develop resistance to the
commonly used drugs at frequencies much
higher than that for C. albicans 50. In the
present study, the Candida species other than
albicans and glabrata showed variable
patterns of resistance and sensitivity and
most of them were sensitive to Nystatin
except some isolates of C. krusei and C.
guilliermondii. Mashburn and Facumv
suggested that uncomplicated vaginal
candidiasis is easily treated with topical
azole antifungal medications in single or
short-term doses. This class of drugs is
usually more effective than the older
nystatin class of drugs. Capoor et al.46
reported that the spectrum of candidiasis
has changed with the emergence of non-
candida species and acquired antifungal
resistance. Other non-Candida species such
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as Saccharomyces cervisiae and Debaryomyces
hansenii were sensitive to most of the tested
antifungal drugs. While Rhodotorula rubra,
Rh. Minuta Trichosporon mucoides, Pichia
ohmeri and Cryptococcus neoformans were
variable in their resistance and sensitivity
pattern towards the tested antifungal drugs.
. Many yeasts and molds are known to
secrete extracellular proteases'f For Candida
species, some investigators have reported
the determination of proteolytic activity'<
whereas others have detected no activity's,
This discrepancy may be attributed to the
conditions used for eliciting and measuring
protease activity. In this study, it was found
that the level of proteolytic enzyme was low
during the earlier exponential growth phase
and reached its maximum value after 72
hours. This clearly shows a direct
correlation between the growth rate of yeast
cells and the proteolytic activities of Candida
isolates. This correlation was also reported
by56 who connected between the
proteolytic production and the growth rate
of yeast cells. Many workers agreed that
Candida species need 72 hours, incubation
time for the maximum protease
productionv-", In this study, the neutral
proteases (pH 6.5) were released in
appreciable amount; 685 umol/ml. in case of
C. albicans. This followed by alkaline
proteases 643 umol/ml. These results
coincide with that of Dostal et al.( 2003) who
reported that the pH value was the critical
factor in proteolytic activity because
relatively small pH shifts can cause changes
in extracellular proteolytic activity. Also,
these results were supported by Taylor et
al.53 who found that the human vaginal
infections were accompanied by elevation of
pH values (neutral to alkaline) and
subsequently the protease activity reached
to the maximum levels. Odds" and Fidel et
al.59 reported that Candida albicans produces
a higher amount of proteases in comparison
with other Candida species.
Conclusion
The incidence of fungal infection and vulvo
vaginal candidiasis is increasing rapidly, in
relation to the growing number of diabetic
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patients and immunocompromised
individuals in the population.
Candida albicans is the most common cause
of Mycotic Vulvovaginitis . Other non-
albicans species such as Candida glabrata and
tropicalis , which are increasing in frequency
are also involved . Topical and oral
antifungal therapies are effective.
Resistance of the Candida spp. towards the
commonly used antifungal drugs is
increasing.
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